Auto-antibodies to type I IFNs can underlie adverse reactions to yellow fever live attenuated vaccine
Yellow fever virus (YFV) live attenuated vaccine can, in rare cases, cause life-threatening disease, typically in patients with no previous history of severe viral illness. Autosomal recessive (AR) complete IFNAR1 deficiency was reported in one 12-yr-old patient. Here, we studied seven other previou...
Saved in:
| Published in | The Journal of experimental medicine Vol. 218; no. 4 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Rockefeller University Press
05.04.2021
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0022-1007 1540-9538 1540-9538 |
| DOI | 10.1084/jem.20202486 |
Cover
| Abstract | Yellow fever virus (YFV) live attenuated vaccine can, in rare cases, cause life-threatening disease, typically in patients with no previous history of severe viral illness. Autosomal recessive (AR) complete IFNAR1 deficiency was reported in one 12-yr-old patient. Here, we studied seven other previously healthy patients aged 13 to 80 yr with unexplained life-threatening YFV vaccine–associated disease. One 13-yr-old patient had AR complete IFNAR2 deficiency. Three other patients vaccinated at the ages of 47, 57, and 64 yr had high titers of circulating auto-Abs against at least 14 of the 17 individual type I IFNs. These antibodies were recently shown to underlie at least 10% of cases of life-threatening COVID-19 pneumonia. The auto-Abs were neutralizing in vitro, blocking the protective effect of IFN-α2 against YFV vaccine strains. AR IFNAR1 or IFNAR2 deficiency and neutralizing auto-Abs against type I IFNs thus accounted for more than half the cases of life-threatening YFV vaccine-associated disease studied here. Previously healthy subjects could be tested for both predispositions before anti-YFV vaccination. |
|---|---|
| AbstractList | Yellow fever virus (YFV) live attenuated vaccine can, in rare cases, cause life-threatening disease, typically in patients with no previous history of severe viral illness. Autosomal recessive (AR) complete IFNAR1 deficiency was reported in one 12-yr-old patient. Here, we studied seven other previously healthy patients aged 13 to 80 yr with unexplained life-threatening YFV vaccine-associated disease. One 13-yr-old patient had AR complete IFNAR2 deficiency. Three other patients vaccinated at the ages of 47, 57, and 64 yr had high titers of circulating auto-Abs against at least 14 of the 17 individual type I IFNs. These antibodies were recently shown to underlie at least 10% of cases of life-threatening COVID-19 pneumonia. The auto-Abs were neutralizing in vitro, blocking the protective effect of IFN-α2 against YFV vaccine strains. AR IFNAR1 or IFNAR2 deficiency and neutralizing auto-Abs against type I IFNs thus accounted for more than half the cases of life-threatening YFV vaccine-associated disease studied here. Previously healthy subjects could be tested for both predispositions before anti-YFV vaccination.Yellow fever virus (YFV) live attenuated vaccine can, in rare cases, cause life-threatening disease, typically in patients with no previous history of severe viral illness. Autosomal recessive (AR) complete IFNAR1 deficiency was reported in one 12-yr-old patient. Here, we studied seven other previously healthy patients aged 13 to 80 yr with unexplained life-threatening YFV vaccine-associated disease. One 13-yr-old patient had AR complete IFNAR2 deficiency. Three other patients vaccinated at the ages of 47, 57, and 64 yr had high titers of circulating auto-Abs against at least 14 of the 17 individual type I IFNs. These antibodies were recently shown to underlie at least 10% of cases of life-threatening COVID-19 pneumonia. The auto-Abs were neutralizing in vitro, blocking the protective effect of IFN-α2 against YFV vaccine strains. AR IFNAR1 or IFNAR2 deficiency and neutralizing auto-Abs against type I IFNs thus accounted for more than half the cases of life-threatening YFV vaccine-associated disease studied here. Previously healthy subjects could be tested for both predispositions before anti-YFV vaccination. Yellow fever virus (YFV) live attenuated vaccine can, in rare cases, cause life-threatening disease, typically in patients with no previous history of severe viral illness. Autosomal recessive (AR) complete IFNAR1 deficiency was reported in one 12-yr-old patient. Here, we studied seven other previously healthy patients aged 13 to 80 yr with unexplained life-threatening YFV vaccine-associated disease. One 13-yr-old patient had AR complete IFNAR2 deficiency. Three other patients vaccinated at the ages of 47, 57, and 64 yr had high titers of circulating auto-Abs against at least 14 of the 17 individual type I IFNs. These antibodies were recently shown to underlie at least 10% of cases of life-threatening COVID-19 pneumonia. The auto-Abs were neutralizing in vitro, blocking the protective effect of IFN-α2 against YFV vaccine strains. AR IFNAR1 or IFNAR2 deficiency and neutralizing auto-Abs against type I IFNs thus accounted for more than half the cases of life-threatening YFV vaccine-associated disease studied here. Previously healthy subjects could be tested for both predispositions before anti-YFV vaccination. Yellow fever virus live attenuated vaccine can rarely cause life-threatening disease. Inherited IFNAR1 deficiency was previously reported in one patient. Here, we report a patient with inherited IFNAR2 deficiency and three other patients with neutralizing auto-antibodies against type I IFNs. Yellow fever virus (YFV) live attenuated vaccine can, in rare cases, cause life-threatening disease, typically in patients with no previous history of severe viral illness. Autosomal recessive (AR) complete IFNAR1 deficiency was reported in one 12-yr-old patient. Here, we studied seven other previously healthy patients aged 13 to 80 yr with unexplained life-threatening YFV vaccine–associated disease. One 13-yr-old patient had AR complete IFNAR2 deficiency. Three other patients vaccinated at the ages of 47, 57, and 64 yr had high titers of circulating auto-Abs against at least 14 of the 17 individual type I IFNs. These antibodies were recently shown to underlie at least 10% of cases of life-threatening COVID-19 pneumonia. The auto-Abs were neutralizing in vitro , blocking the protective effect of IFN-α2 against YFV vaccine strains. AR IFNAR1 or IFNAR2 deficiency and neutralizing auto-Abs against type I IFNs thus accounted for more than half the cases of life-threatening YFV vaccine-associated disease studied here. Previously healthy subjects could be tested for both predispositions before anti-YFV vaccination. |
| Author | Cobat, Aurélie Schäfer, Johannes Chbihi, Marwa Hoffmann, Hans-Heinrich Jeljeli, Mohamed Maxime MacDonald, Margaret R. Su, Helen C. Azamor, Tamiris Rozenberg, Flore Holland, Steven M. Dinis Ano Bom, Ana Paula Rice, Charles M. Maia, Maria de Lourdes S. Bastard, Paul Gervais, Adrian Rosen, Lindsey B. Lorenzo, Lazaro Rosain, Jérémie Philippot, Quentin Béziat, Vivien Chrabieh, Maya Materna, Marie Miller, Joseph D. Erazo, Lucia V. Araújo da Conceição, Deborah Seligman, Stephen J. Ahmed, Rafi Huits, Ralph Zhang, Shen-Ying de Oliveira, Patricia Mouta Nunes Zhang, Qian Le Voyer, Tom Notarangelo, Luigi D. Pulendran, Bali Seeleuthner, Yoann Homma, Akira Puel, Anne Slesak, Günther Goudouris, Ekaterini Jouanguy, Emmanuelle Abel, Laurent Casanova, Jean-Laurent Yang, Rui Michailidis, Eleftherios Bizien, Lucy |
| AuthorAffiliation | 16 New York Medical College, Valhalla, NY 3 St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY 8 Tropical Medicine Department, Tropenklinik Paul-Lechler-Krankenhaus, Tübingen, Germany 1 Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale U1163, Necker Hospital for Sick Children, Paris, France 13 Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 11 Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases, Division of Scientific Resources, Atlanta, GA 7 Federal University of Rio de Janeiro, Rio de Janeiro, Brazil 9 Emory Vaccine Center and the Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA 12 Department of Clinical Sciences, Institute of Tropical Medicine, Ant |
| AuthorAffiliation_xml | – name: 1 Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale U1163, Necker Hospital for Sick Children, Paris, France – name: 4 Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY – name: 13 Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD – name: 15 Laboratory of Immunology, University of Paris, Cochin Hospital, Assistance Publique–Hôpitaux de Paris, Paris, France – name: 8 Tropical Medicine Department, Tropenklinik Paul-Lechler-Krankenhaus, Tübingen, Germany – name: 16 New York Medical College, Valhalla, NY – name: 10 Institute for Immunity, Transplantation and Infection, Department of Pathology, Department of Microbiology and Immunology, Stanford University, Stanford, CA – name: 5 Bio-Manguinhos, Fiocruz, Ministry of Health, Rio de Janeiro, Brazil – name: 6 Laboratory of Immunological Techniques, Bio-Manguinhos, Fiocruz, Ministry of Health, Rio de Janeiro, Brazil – name: 3 St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY – name: 11 Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases, Division of Scientific Resources, Atlanta, GA – name: 14 Laboratory of Virology, University of Paris, Cochin Hospital, Assistance Publique–Hôpitaux de Paris, Paris, France – name: 12 Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium – name: 17 Howard Hughes Medical Institute, New York, NY – name: 2 University of Paris, Imagine Institute, Paris, France – name: 7 Federal University of Rio de Janeiro, Rio de Janeiro, Brazil – name: 9 Emory Vaccine Center and the Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA |
| Author_xml | – sequence: 1 givenname: Paul orcidid: 0000-0002-5926-8437 surname: Bastard fullname: Bastard, Paul – sequence: 2 givenname: Eleftherios orcidid: 0000-0002-9907-4346 surname: Michailidis fullname: Michailidis, Eleftherios – sequence: 3 givenname: Hans-Heinrich orcidid: 0000-0003-0554-0244 surname: Hoffmann fullname: Hoffmann, Hans-Heinrich – sequence: 4 givenname: Marwa orcidid: 0000-0002-2771-851X surname: Chbihi fullname: Chbihi, Marwa – sequence: 5 givenname: Tom orcidid: 0000-0002-7253-3135 surname: Le Voyer fullname: Le Voyer, Tom – sequence: 6 givenname: Jérémie orcidid: 0000-0002-2822-161X surname: Rosain fullname: Rosain, Jérémie – sequence: 7 givenname: Quentin orcidid: 0000-0003-3429-9605 surname: Philippot fullname: Philippot, Quentin – sequence: 8 givenname: Yoann orcidid: 0000-0002-1878-8567 surname: Seeleuthner fullname: Seeleuthner, Yoann – sequence: 9 givenname: Adrian orcidid: 0000-0002-1083-5787 surname: Gervais fullname: Gervais, Adrian – sequence: 10 givenname: Marie orcidid: 0000-0003-1180-6651 surname: Materna fullname: Materna, Marie – sequence: 11 givenname: Patricia Mouta Nunes orcidid: 0000-0001-6867-398X surname: de Oliveira fullname: de Oliveira, Patricia Mouta Nunes – sequence: 12 givenname: Maria de Lourdes S. orcidid: 0000-0003-4223-9151 surname: Maia fullname: Maia, Maria de Lourdes S. – sequence: 13 givenname: Ana Paula orcidid: 0000-0002-2299-0792 surname: Dinis Ano Bom fullname: Dinis Ano Bom, Ana Paula – sequence: 14 givenname: Tamiris orcidid: 0000-0002-4047-2091 surname: Azamor fullname: Azamor, Tamiris – sequence: 15 givenname: Deborah orcidid: 0000-0003-0320-5397 surname: Araújo da Conceição fullname: Araújo da Conceição, Deborah – sequence: 16 givenname: Ekaterini orcidid: 0000-0002-1937-9124 surname: Goudouris fullname: Goudouris, Ekaterini – sequence: 17 givenname: Akira orcidid: 0000-0002-4641-8491 surname: Homma fullname: Homma, Akira – sequence: 18 givenname: Günther orcidid: 0000-0002-8149-2910 surname: Slesak fullname: Slesak, Günther – sequence: 19 givenname: Johannes orcidid: 0000-0001-8617-253X surname: Schäfer fullname: Schäfer, Johannes – sequence: 20 givenname: Bali orcidid: 0000-0001-6517-4333 surname: Pulendran fullname: Pulendran, Bali – sequence: 21 givenname: Joseph D. orcidid: 0000-0002-9301-0384 surname: Miller fullname: Miller, Joseph D. – sequence: 22 givenname: Ralph orcidid: 0000-0001-8803-9468 surname: Huits fullname: Huits, Ralph – sequence: 23 givenname: Rui orcidid: 0000-0003-4427-2158 surname: Yang fullname: Yang, Rui – sequence: 24 givenname: Lindsey B. orcidid: 0000-0001-5894-3878 surname: Rosen fullname: Rosen, Lindsey B. – sequence: 25 givenname: Lucy orcidid: 0000-0001-9163-9122 surname: Bizien fullname: Bizien, Lucy – sequence: 26 givenname: Lazaro orcidid: 0000-0001-6648-8684 surname: Lorenzo fullname: Lorenzo, Lazaro – sequence: 27 givenname: Maya orcidid: 0000-0003-0772-4805 surname: Chrabieh fullname: Chrabieh, Maya – sequence: 28 givenname: Lucia V. orcidid: 0000-0002-3975-5609 surname: Erazo fullname: Erazo, Lucia V. – sequence: 29 givenname: Flore orcidid: 0000-0001-7212-2021 surname: Rozenberg fullname: Rozenberg, Flore – sequence: 30 givenname: Mohamed Maxime orcidid: 0000-0001-9561-8847 surname: Jeljeli fullname: Jeljeli, Mohamed Maxime – sequence: 31 givenname: Vivien orcidid: 0000-0002-4020-824X surname: Béziat fullname: Béziat, Vivien – sequence: 32 givenname: Steven M. orcidid: 0000-0003-3207-5464 surname: Holland fullname: Holland, Steven M. – sequence: 33 givenname: Aurélie orcidid: 0000-0001-7209-6257 surname: Cobat fullname: Cobat, Aurélie – sequence: 34 givenname: Luigi D. orcidid: 0000-0002-8335-0262 surname: Notarangelo fullname: Notarangelo, Luigi D. – sequence: 35 givenname: Helen C. orcidid: 0000-0002-5582-9110 surname: Su fullname: Su, Helen C. – sequence: 36 givenname: Rafi orcidid: 0000-0002-9591-2621 surname: Ahmed fullname: Ahmed, Rafi – sequence: 37 givenname: Anne orcidid: 0000-0003-2603-0323 surname: Puel fullname: Puel, Anne – sequence: 38 givenname: Shen-Ying orcidid: 0000-0002-9449-3672 surname: Zhang fullname: Zhang, Shen-Ying – sequence: 39 givenname: Laurent orcidid: 0000-0001-7016-6493 surname: Abel fullname: Abel, Laurent – sequence: 40 givenname: Stephen J. orcidid: 0000-0001-7036-3323 surname: Seligman fullname: Seligman, Stephen J. – sequence: 41 givenname: Qian orcidid: 0000-0002-9040-3289 surname: Zhang fullname: Zhang, Qian – sequence: 42 givenname: Margaret R. orcidid: 0000-0001-5177-2068 surname: MacDonald fullname: MacDonald, Margaret R. – sequence: 43 givenname: Emmanuelle orcidid: 0000-0002-7358-9157 surname: Jouanguy fullname: Jouanguy, Emmanuelle – sequence: 44 givenname: Charles M. orcidid: 0000-0003-3087-8079 surname: Rice fullname: Rice, Charles M. – sequence: 45 givenname: Jean-Laurent orcidid: 0000-0002-7782-4169 surname: Casanova fullname: Casanova, Jean-Laurent |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33544838$$D View this record in MEDLINE/PubMed |
| BookMark | eNptkc1PHSEUxUljU5-2u64bli4cCwwMzMbEGD9eYtqNrgkDdxQzD16Bec3774ufscaQwOL-OPfec_bQTogBEPpOyREliv-8h9URI_Vw1X1CCyo4aXrRqh20IISxhhIid9FezveEUM5F9wXttq3gXLVqgeBkLrExofghOg8Zl4jLdg14iZfnvzK2JuA5OEiTB2zcBlIGnMDY4mN4pLcwTfEvHqHW8OQ3FSsFwmwKOLwx1voAX9Hn0UwZvj2_--jm_Oz69LK5-n2xPD25aiwXpDSUgZVCWakG6fqhjm-6oe1cJ0jv1NiNg2QtH4k0qnfMcTb2ZuDCSUakYp1t99Hxk-56HlbgLISSzKTXya9M2upovP6_Evydvo0bLZWkXMgqcPAskOKfGXLRK59t3dAEiHPW1WRJRVvviv542-u1yYu3FTh8AmyKOScYXxFK9EN0ukanX6KrOHuHW1_Mg811Uj99_OkfnRGdtw |
| CitedBy_id | crossref_primary_10_1111_joim_13628 crossref_primary_10_1084_jem_20241413 crossref_primary_10_1016_j_tmaid_2024_102697 crossref_primary_10_35339_msz_2024_93_3_bbs crossref_primary_10_1002_eji_202250133 crossref_primary_10_1080_1744666X_2023_2208863 crossref_primary_10_3389_fimmu_2022_988536 crossref_primary_10_1590_1678_4685_gmb_2023_0128 crossref_primary_10_1016_j_jaci_2024_12_1078 crossref_primary_10_3201_eid2903_220989 crossref_primary_10_1007_s10875_021_01023_5 crossref_primary_10_1016_j_jaci_2023_02_003 crossref_primary_10_1038_s41467_022_34709_4 crossref_primary_10_1111_febs_15961 crossref_primary_10_3389_fimmu_2024_1327784 crossref_primary_10_1016_j_clim_2021_108851 crossref_primary_10_7554_eLife_71047 crossref_primary_10_3390_pathogens10060634 crossref_primary_10_1084_jem_20220028 crossref_primary_10_1001_jamadermatol_2022_0055 crossref_primary_10_1038_s41586_024_08119_z crossref_primary_10_1002_eji_202250307 crossref_primary_10_3390_v15051215 crossref_primary_10_1016_j_exphem_2021_09_005 crossref_primary_10_1111_imr_13304 crossref_primary_10_1172_jci_insight_163150 crossref_primary_10_1111_imr_13300 crossref_primary_10_1007_s10875_021_01204_2 crossref_primary_10_1016_j_cellsig_2021_110121 crossref_primary_10_1093_jtm_taad160 crossref_primary_10_1007_s10875_021_01166_5 crossref_primary_10_1080_22221751_2021_2008772 crossref_primary_10_1007_s10875_024_01757_y crossref_primary_10_1016_j_coi_2021_08_001 crossref_primary_10_1016_j_jmii_2025_02_002 crossref_primary_10_3390_cells11142198 crossref_primary_10_1126_science_abj7965 crossref_primary_10_3389_fviro_2021_692105 crossref_primary_10_3389_fped_2021_723532 crossref_primary_10_1007_s10875_021_01118_z crossref_primary_10_3390_jpm12121948 crossref_primary_10_4049_jimmunol_2200538 crossref_primary_10_1172_JCI166283 crossref_primary_10_1016_j_sciaf_2024_e02240 crossref_primary_10_1016_j_immuni_2024_03_015 crossref_primary_10_1084_jem_20231152 crossref_primary_10_1038_s41586_024_07213_6 crossref_primary_10_1371_journal_pbio_3001709 crossref_primary_10_1016_j_vaccine_2025_126721 crossref_primary_10_1056_NEJMoa2210665 crossref_primary_10_1084_jem_20211211 crossref_primary_10_1172_JCI168321 crossref_primary_10_1126_sciimmunol_adm8185 crossref_primary_10_1146_annurev_micro_092123_022855 crossref_primary_10_1007_s10875_023_01451_5 crossref_primary_10_1038_s41541_024_00829_9 crossref_primary_10_1084_jem_20212427 crossref_primary_10_1016_j_cell_2022_07_004 crossref_primary_10_1016_j_cmet_2022_04_009 crossref_primary_10_1016_j_omtm_2022_03_010 crossref_primary_10_1146_annurev_immunol_101721_065201 crossref_primary_10_1038_s41467_023_41600_3 crossref_primary_10_1007_s10875_021_01203_3 crossref_primary_10_1016_S1773_035X_21_00210_0 crossref_primary_10_1038_s41587_021_01037_9 crossref_primary_10_1084_jem_20240942 crossref_primary_10_3390_cells13050369 crossref_primary_10_1016_j_isci_2023_107084 crossref_primary_10_1016_j_xcrm_2022_100894 crossref_primary_10_1002_rmv_70007 crossref_primary_10_1016_j_ebiom_2022_104414 crossref_primary_10_1038_s41586_023_06717_x crossref_primary_10_1016_j_autrev_2021_103012 crossref_primary_10_1002_cpz1_511 crossref_primary_10_1002_cti2_1327 crossref_primary_10_1084_jem_20210554 crossref_primary_10_1016_j_cell_2022_12_038 crossref_primary_10_1007_s10875_024_01708_7 crossref_primary_10_7554_eLife_78550 crossref_primary_10_1016_j_coi_2022_01_003 crossref_primary_10_1007_s10875_024_01683_z crossref_primary_10_1016_j_jid_2021_04_022 crossref_primary_10_1128_spectrum_02246_22 crossref_primary_10_1073_pnas_2200413119 crossref_primary_10_1038_s41590_021_01030_z crossref_primary_10_3390_life12111918 crossref_primary_10_1016_j_trim_2023_101791 crossref_primary_10_1073_pnas_2402983121 crossref_primary_10_3390_pathogens10091197 crossref_primary_10_1016_j_ejim_2024_04_006 crossref_primary_10_1084_jem_20242039 crossref_primary_10_1186_s12974_024_03228_y crossref_primary_10_1038_s41582_024_01000_7 crossref_primary_10_1038_s41586_022_04447_0 crossref_primary_10_1016_j_coi_2024_102427 crossref_primary_10_1016_S1474_4422_24_00263_1 crossref_primary_10_1038_s41590_024_01815_y crossref_primary_10_1146_annurev_immunol_101921_050835 crossref_primary_10_3390_vaccines12060665 crossref_primary_10_1007_s10875_024_01843_1 crossref_primary_10_1126_sciimmunol_abl4340 crossref_primary_10_1172_JCI178263 crossref_primary_10_1038_s41577_023_00933_2 crossref_primary_10_1126_sciimmunol_abp8966 crossref_primary_10_1126_sciimmunol_abl4348 crossref_primary_10_1136_ard_2022_222549 crossref_primary_10_3390_genes13122355 crossref_primary_10_1007_s10875_021_01168_3 crossref_primary_10_1126_science_abn9649 crossref_primary_10_1016_j_cmi_2022_02_022 crossref_primary_10_3390_diagnostics12071711 crossref_primary_10_1007_s10875_024_01774_x crossref_primary_10_1007_s10875_024_01814_6 crossref_primary_10_1007_s10096_023_04688_5 crossref_primary_10_1084_jem_20211387 crossref_primary_10_3389_fimmu_2021_798389 crossref_primary_10_1016_j_cellimm_2024_104807 crossref_primary_10_1084_jem_20220131 crossref_primary_10_1093_cei_uxae062 crossref_primary_10_1084_jem_20220491 crossref_primary_10_1126_sciimmunol_adq1697 crossref_primary_10_15406_ogij_2023_14_00710 crossref_primary_10_1093_infdis_jiae036 crossref_primary_10_1172_JCI154886 crossref_primary_10_1186_s43042_024_00604_4 crossref_primary_10_1084_jem_20231353 crossref_primary_10_1084_jem_20230661 crossref_primary_10_2139_ssrn_4115477 crossref_primary_10_1038_s43587_021_00156_x crossref_primary_10_1111_imr_13297 crossref_primary_10_1007_s10875_022_01308_3 crossref_primary_10_1016_j_jaip_2021_05_004 crossref_primary_10_1002_iid3_1056 crossref_primary_10_1016_j_coi_2021_07_011 crossref_primary_10_1016_j_coi_2021_05_006 crossref_primary_10_1111_pai_13632 crossref_primary_10_1016_j_coi_2021_05_007 crossref_primary_10_1084_jem_20210446 crossref_primary_10_1051_medsci_2025018 crossref_primary_10_3390_ijms23094547 crossref_primary_10_1016_S1773_035X_22_00013_2 crossref_primary_10_1016_j_coi_2023_102355 crossref_primary_10_1084_jem_20220514 |
| Cites_doi | 10.1586/14760584.4.4.553 10.4161/hv.1.5.2221 10.1084/jem.20180628 10.1172/JCI139980 10.1126/science.abd4585 10.1007/s10875-020-00758-x 10.1101/gr.107524.110 10.1074/jbc.M002518200 10.1038/ng.2892 10.1016/S0140-6736(01)05326-0 10.1002/art.39607 10.1038/ng1097 10.1038/ncomms13992 10.1101/gr.176601 10.1016/j.vaccine.2014.05.003 10.1002/art.40792 10.1055/s-0043-114729 10.1086/590187 10.1080/14760584.2016.1180250 10.1007/s10875-019-00737-x 10.1038/s41586-020-3035-9 10.1016/S0140-6736(01)05341-7 10.1016/j.immuni.2006.10.007 10.1126/scitranslmed.aac4227 10.1016/S0140-6736(01)05327-2 10.1083/jcb.201412049 10.1016/j.vaccine.2014.08.051 10.4049/jimmunol.129.1.1 10.1093/jtm/taaa172 10.1084/jem.20140280 10.1038/nmeth0410-248 10.1073/pnas.1220098110 10.1093/jtm/taw045 10.1016/j.medj.2020.12.001 10.1084/jem.20182295 10.1093/bioinformatics/btp324 10.1172/JCI80477 10.1007/s00439-020-02180-0 10.1038/nmeth.3739 10.1126/science.abd4570 10.1016/j.jaci.2019.02.019 10.1371/journal.pmed.0030289 10.1016/j.immuni.2019.03.025 10.1371/journal.ppat.1001255 10.1093/cid/ciaa1790 10.1126/sciimmunol.abb1662 10.3390/cells9010072 10.1093/bioinformatics/btp352 10.1016/j.vaccine.2012.04.067 |
| ContentType | Journal Article |
| Copyright | 2021 Bastard et al. 2021 Bastard et al. 2021 |
| Copyright_xml | – notice: 2021 Bastard et al. – notice: 2021 Bastard et al. 2021 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
| DOI | 10.1084/jem.20202486 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE CrossRef |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| DocumentTitleAlternate | Antibodies to type I IFNs and yellow fever vaccine |
| EISSN | 1540-9538 |
| ExternalDocumentID | PMC7871457 33544838 10_1084_jem_20202486 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: NIAID NIH HHS grantid: U19 AI090023 – fundername: NIAID NIH HHS grantid: U19 AI057266 – fundername: NCATS NIH HHS grantid: UL1 TR001866 – fundername: NIAID NIH HHS grantid: R01 AI124690 – fundername: NHGRI NIH HHS grantid: UM1 HG006504 – fundername: NIAID NIH HHS grantid: R01 AI088364 – fundername: NHGRI NIH HHS grantid: U24 HG008956 – fundername: NIAID NIH HHS grantid: R38 AI140299 – fundername: NIA NIH HHS grantid: U54 AG062334 – fundername: ; – fundername: ; grantid: ANR-10-LABX-62-IBEID – fundername: ; grantid: EA20170638020 – fundername: ; grantid: R01AI088364 – fundername: ; grantid: UL1 TR001866 – fundername: ; grantid: ANR-10-IAHU-01 – fundername: ; grantid: UM1HG006504; U24HG008956 – fundername: ; grantid: EQU201903007798 – fundername: ; grantid: 1R01AI124690 |
| GroupedDBID | --- -~X 18M 29K 2WC 36B 4.4 53G 5GY 5RE 5VS AAYXX ABOCM ABZEH ACGFO ACNCT ACPRK ADBBV AENEX AFOSN AFRAH ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BTFSW C45 CITATION CS3 D-I DIK DU5 E3Z EBS EMB F5P F9R GX1 H13 HYE IH2 KQ8 L7B N9A O5R O5S OK1 P2P P6G R.V RHI SJN TR2 TRP UHB W8F WOQ CGR CUY CVF ECM EIF NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c450t-12ec758c78b7d9b002a6b36d6509d8f6fb7234f07a89d2d42f9ab45d7207826c3 |
| ISSN | 0022-1007 1540-9538 |
| IngestDate | Thu Aug 21 14:00:36 EDT 2025 Thu Sep 04 17:35:33 EDT 2025 Wed Sep 10 03:20:21 EDT 2025 Tue Jul 01 00:41:15 EDT 2025 Thu Apr 24 23:00:03 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Language | English |
| License | 2021 Bastard et al. This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/). |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c450t-12ec758c78b7d9b002a6b36d6509d8f6fb7234f07a89d2d42f9ab45d7207826c3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 M.R. MacDonald, E. Jouanguy, C.M. Rice, and J.-L. Casanova contributed equally to this paper. E. Michailidis, H.-H. Hoffmann, and M. Chbihi contributed equally to this paper. Disclosures: A. Homma reported, "Our institution is a non-profit producer of the yellow fever vaccine. We are public institution, part of our Ministry of Health, and provide vaccine only for National Immunization Program and UNICEF, PAHO Revolving Fund, GAVI, and WHO. We are very much interested to know all relevant scientific issues involved with our vaccine." J.L. Casanova reported a patent to application number 63/055,155, filed July 22, 2020 pending. No other disclosures were reported. S.J. Seligman and Q. Zhang contributed equally to this paper. |
| ORCID | 0000-0001-5177-2068 0000-0002-7253-3135 0000-0002-7358-9157 0000-0001-7209-6257 0000-0002-4020-824X 0000-0001-6648-8684 0000-0003-1180-6651 0000-0002-5582-9110 0000-0002-8335-0262 0000-0002-4641-8491 0000-0002-9449-3672 0000-0002-5926-8437 0000-0002-9301-0384 0000-0001-8803-9468 0000-0001-6867-398X 0000-0001-8617-253X 0000-0001-6517-4333 0000-0002-3975-5609 0000-0002-1878-8567 0000-0001-7016-6493 0000-0003-3429-9605 0000-0003-3087-8079 0000-0001-7212-2021 0000-0003-0320-5397 0000-0003-2603-0323 0000-0002-2822-161X 0000-0001-9561-8847 0000-0002-1083-5787 0000-0003-4223-9151 0000-0002-8149-2910 0000-0003-0772-4805 0000-0002-4047-2091 0000-0002-1937-9124 0000-0002-9907-4346 0000-0002-2299-0792 0000-0001-9163-9122 0000-0002-2771-851X 0000-0002-9040-3289 0000-0003-4427-2158 0000-0002-9591-2621 0000-0003-0554-0244 0000-0003-3207-5464 0000-0002-7782-4169 0000-0001-7036-3323 0000-0001-5894-3878 |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC7871457 |
| PMID | 33544838 |
| PQID | 2487153487 |
| PQPubID | 23479 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_7871457 proquest_miscellaneous_2487153487 pubmed_primary_33544838 crossref_primary_10_1084_jem_20202486 crossref_citationtrail_10_1084_jem_20202486 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2021-04-05 |
| PublicationDateYYYYMMDD | 2021-04-05 |
| PublicationDate_xml | – month: 04 year: 2021 text: 2021-04-05 day: 05 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | The Journal of experimental medicine |
| PublicationTitleAlternate | J Exp Med |
| PublicationYear | 2021 |
| Publisher | Rockefeller University Press |
| Publisher_xml | – name: Rockefeller University Press |
| References | Bastard (2023072706474702600_bib3) 2020; 370 Martin (2023072706474702600_bib26) 2001; 358 Adzhubei (2023072706474702600_bib1) 2010; 7 Howe (2023072706474702600_bib16) 2019; 9 Bravo García-Morato (2023072706474702600_bib5) 2019; 144 Hambleton (2023072706474702600_bib13) 2013; 110 Martins (2023072706474702600_bib27) 2014; 32 Sanchez-Felipe (2023072706474702600_bib38) 2020 Li (2023072706474702600_bib24) 2009; 25 Zhang (2023072706474702600_bib48) 2020; 1 Gupta (2023072706474702600_bib12) 2016; 68 Walter (2023072706474702600_bib44) 2015; 125 Bastard (2023072706474702600_bib2) 2020; 131 Slesak (2023072706474702600_bib41) 2017; 142 Wilmes (2023072706474702600_bib46) 2015; 209 Russell-Harde (2023072706474702600_bib37) 2000; 275 Panem (2023072706474702600_bib35) 1982; 129 Duncan (2023072706474702600_bib7) 2015; 7 Ku (2023072706474702600_bib20) 2020; 139 Itan (2023072706474702600_bib17) 2016; 13 Lindsey (2023072706474702600_bib25) 2016; 23 Monath (2023072706474702600_bib31) 2005; 4 Notarangelo (2023072706474702600_bib34) 2020; 5 Li (2023072706474702600_bib23) 2009; 25 Watford (2023072706474702600_bib45) 2006; 25 McKenna (2023072706474702600_bib29) 2010; 20 Kircher (2023072706474702600_bib18) 2014; 46 Kreins (2023072706474702600_bib19) 2015; 212 Meager (2023072706474702600_bib30) 2006; 3 Lazear (2023072706474702600_bib21) 2019; 50 Seligman (2023072706474702600_bib40) 2016; 15 Seligman (2023072706474702600_bib39) 2014; 32 Yi (2023072706474702600_bib47) 2011; 7 Dupuis (2023072706474702600_bib8) 2003; 33 Chan (2023072706474702600_bib6) 2001; 358 Gershman (2023072706474702600_bib10) 2012; 30 Gothe (2023072706474702600_bib11) 2020 Hernandez (2023072706474702600_bib14) 2018; 215 Zhang (2023072706474702600_bib49) 2020; 370 Hernandez (2023072706474702600_bib15) 2019; 216 Lecomte (2023072706474702600_bib22) 2020; 27 Pulendran (2023072706474702600_bib36) 2008; 198 Bousfiha (2023072706474702600_bib4) 2020; 40 Vasconcelos (2023072706474702600_bib43) 2001; 358 Tangye (2023072706474702600_bib42) 2020; 40 Ng (2023072706474702600_bib33) 2001; 11 Eletto (2023072706474702600_bib9) 2016; 7 Monath (2023072706474702600_bib32) 2005; 1 Mathian (2023072706474702600_bib28) 2019; 71 |
| References_xml | – volume: 4 start-page: 553 year: 2005 ident: 2023072706474702600_bib31 article-title: Yellow fever vaccine publication-title: Expert Rev. Vaccines. doi: 10.1586/14760584.4.4.553 – volume: 1 start-page: 207 year: 2005 ident: 2023072706474702600_bib32 article-title: Yellow fever 17D vaccine safety and immunogenicity in the elderly publication-title: Hum. Vaccin. doi: 10.4161/hv.1.5.2221 – volume: 215 start-page: 2567 year: 2018 ident: 2023072706474702600_bib14 article-title: Life-threatening influenza pneumonitis in a child with inherited IRF9 deficiency publication-title: J. Exp. Med. doi: 10.1084/jem.20180628 – volume: 131 start-page: e139980 year: 2020 ident: 2023072706474702600_bib2 article-title: Herpes simplex encephalitis in a patient with a distinctive form of inherited IFNAR1 deficiency publication-title: J. Clin. Invest. doi: 10.1172/JCI139980 – volume: 370 year: 2020 ident: 2023072706474702600_bib3 article-title: Autoantibodies against type I IFNs in patients with life-threatening COVID-19 publication-title: Science. doi: 10.1126/science.abd4585 – volume: 40 start-page: 66 year: 2020 ident: 2023072706474702600_bib4 article-title: Human Inborn Errors of Immunity: 2019 Update of the IUIS Phenotypical Classification publication-title: J. Clin. Immunol. doi: 10.1007/s10875-020-00758-x – volume: 20 start-page: 1297 year: 2010 ident: 2023072706474702600_bib29 article-title: The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data publication-title: Genome Res. doi: 10.1101/gr.107524.110 – volume: 275 start-page: 23981 year: 2000 ident: 2023072706474702600_bib37 article-title: Role of the intracellular domain of the human type I interferon receptor 2 chain (IFNAR2c) in interferon signaling. Expression of IFNAR2c truncation mutants in U5A cells publication-title: J. Biol. Chem. doi: 10.1074/jbc.M002518200 – volume: 46 start-page: 310 year: 2014 ident: 2023072706474702600_bib18 article-title: A general framework for estimating the relative pathogenicity of human genetic variants publication-title: Nat. Genet. doi: 10.1038/ng.2892 – volume: 358 start-page: 91 year: 2001 ident: 2023072706474702600_bib43 article-title: Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases publication-title: Lancet. doi: 10.1016/S0140-6736(01)05326-0 – volume: 68 start-page: 1677 year: 2016 ident: 2023072706474702600_bib12 article-title: Distinct Functions of Autoantibodies Against Interferon in Systemic Lupus Erythematosus: A Comprehensive Analysis of Anticytokine Autoantibodies in Common Rheumatic Diseases publication-title: Arthritis Rheumatol. doi: 10.1002/art.39607 – volume: 33 start-page: 388 year: 2003 ident: 2023072706474702600_bib8 article-title: Impaired response to interferon-alpha/beta and lethal viral disease in human STAT1 deficiency publication-title: Nat. Genet. doi: 10.1038/ng1097 – volume: 7 start-page: 13992 year: 2016 ident: 2023072706474702600_bib9 article-title: Biallelic JAK1 mutations in immunodeficient patient with mycobacterial infection publication-title: Nat. Commun. doi: 10.1038/ncomms13992 – volume: 11 start-page: 863 year: 2001 ident: 2023072706474702600_bib33 article-title: Predicting deleterious amino acid substitutions publication-title: Genome Res. doi: 10.1101/gr.176601 – volume: 32 start-page: 6676 year: 2014 ident: 2023072706474702600_bib27 article-title: Adverse events following yellow fever immunization: Report and analysis of 67 neurological cases in Brazil publication-title: Vaccine. doi: 10.1016/j.vaccine.2014.05.003 – volume: 71 start-page: 756 year: 2019 ident: 2023072706474702600_bib28 article-title: Monitoring Disease Activity in Systemic Lupus Erythematosus With Single-Molecule Array Digital Enzyme-Linked Immunosorbent Assay Quantification of Serum Interferon-α publication-title: Arthritis Rheumatol. doi: 10.1002/art.40792 – volume: 142 start-page: 1219 year: 2017 ident: 2023072706474702600_bib41 article-title: [Severe Yellow fever vaccine-associated disease: a case report and current overview] publication-title: Dtsch. Med. Wochenschr doi: 10.1055/s-0043-114729 – volume: 198 start-page: 500 year: 2008 ident: 2023072706474702600_bib36 article-title: Case of yellow fever vaccine--associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes publication-title: J. Infect. Dis. doi: 10.1086/590187 – volume: 15 start-page: 681 year: 2016 ident: 2023072706474702600_bib40 article-title: Yellow fever vaccine: worthy friend or stealthy foe? publication-title: Expert Rev. Vaccines. doi: 10.1080/14760584.2016.1180250 – volume: 40 start-page: 24 year: 2020 ident: 2023072706474702600_bib42 article-title: Human Inborn Errors of Immunity: 2019 Update on the Classification from the International Union of Immunological Societies Expert Committee publication-title: J. Clin. Immunol. doi: 10.1007/s10875-019-00737-x – year: 2020 ident: 2023072706474702600_bib38 article-title: A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate publication-title: Nature. doi: 10.1038/s41586-020-3035-9 – volume: 358 start-page: 121 year: 2001 ident: 2023072706474702600_bib6 article-title: Hepatitis and death following vaccination with 17D-204 yellow fever vaccine publication-title: Lancet. doi: 10.1016/S0140-6736(01)05341-7 – volume: 25 start-page: 695 year: 2006 ident: 2023072706474702600_bib45 article-title: Human tyk2 kinase deficiency: another primary immunodeficiency syndrome publication-title: Immunity. doi: 10.1016/j.immuni.2006.10.007 – volume: 7 year: 2015 ident: 2023072706474702600_bib7 article-title: Human IFNAR2 deficiency: Lessons for antiviral immunity publication-title: Sci. Transl. Med. doi: 10.1126/scitranslmed.aac4227 – volume: 358 start-page: 98 year: 2001 ident: 2023072706474702600_bib26 article-title: Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases publication-title: Lancet. doi: 10.1016/S0140-6736(01)05327-2 – volume: 209 start-page: 579 year: 2015 ident: 2023072706474702600_bib46 article-title: Receptor dimerization dynamics as a regulatory valve for plasticity of type I interferon signaling publication-title: J. Cell Biol. doi: 10.1083/jcb.201412049 – volume: 32 start-page: 5769 year: 2014 ident: 2023072706474702600_bib39 article-title: Risk groups for yellow fever vaccine-associated viscerotropic disease (YEL-AVD) publication-title: Vaccine. doi: 10.1016/j.vaccine.2014.08.051 – volume: 129 start-page: 1 year: 1982 ident: 2023072706474702600_bib35 article-title: Antibodies to alpha-interferon in a patient with systemic lupus erythematosus publication-title: J. Immunol. doi: 10.4049/jimmunol.129.1.1 – volume: 27 year: 2020 ident: 2023072706474702600_bib22 article-title: A clinician’s perspective on yellow fever vaccine-associated neurotropic disease publication-title: J. Travel Med. doi: 10.1093/jtm/taaa172 – volume: 212 start-page: 1641 year: 2015 ident: 2023072706474702600_bib19 article-title: Human TYK2 deficiency: Mycobacterial and viral infections without hyper-IgE syndrome publication-title: J. Exp. Med. doi: 10.1084/jem.20140280 – volume: 7 start-page: 248 year: 2010 ident: 2023072706474702600_bib1 article-title: A method and server for predicting damaging missense mutations publication-title: Nat. Methods. doi: 10.1038/nmeth0410-248 – volume: 110 start-page: 3053 year: 2013 ident: 2023072706474702600_bib13 article-title: STAT2 deficiency and susceptibility to viral illness in humans publication-title: Proc. Natl. Acad. Sci. USA. doi: 10.1073/pnas.1220098110 – volume: 23 year: 2016 ident: 2023072706474702600_bib25 article-title: Adverse event reports following yellow fever vaccination, 2007-13 publication-title: J. Travel Med. doi: 10.1093/jtm/taw045 – volume: 1 start-page: 14 year: 2020 ident: 2023072706474702600_bib48 article-title: Life-Threatening COVID-19: Defective Interferons Unleash Excessive Inflammation publication-title: Med (N Y). doi: 10.1016/j.medj.2020.12.001 – volume: 216 start-page: 2057 year: 2019 ident: 2023072706474702600_bib15 article-title: Inherited IFNAR1 deficiency in otherwise healthy patients with adverse reaction to measles and yellow fever live vaccines publication-title: J. Exp. Med. doi: 10.1084/jem.20182295 – volume: 25 start-page: 1754 year: 2009 ident: 2023072706474702600_bib23 article-title: Fast and accurate short read alignment with Burrows-Wheeler transform publication-title: Bioinformatics. doi: 10.1093/bioinformatics/btp324 – volume: 125 start-page: 4135 year: 2015 ident: 2023072706474702600_bib44 article-title: Broad-spectrum antibodies against self-antigens and cytokines in RAG deficiency publication-title: J. Clin. Invest. doi: 10.1172/JCI80477 – volume: 139 start-page: 783 year: 2020 ident: 2023072706474702600_bib20 article-title: Autoantibodies against cytokines: phenocopies of primary immunodeficiencies? publication-title: Hum. Genet. doi: 10.1007/s00439-020-02180-0 – volume: 13 start-page: 109 year: 2016 ident: 2023072706474702600_bib17 article-title: The mutation significance cutoff: gene-level thresholds for variant predictions publication-title: Nat. Methods. doi: 10.1038/nmeth.3739 – volume: 370 year: 2020 ident: 2023072706474702600_bib49 article-title: Inborn errors of type I IFN immunity in patients with life-threatening COVID-19 publication-title: Science. doi: 10.1126/science.abd4570 – volume: 144 start-page: 309 year: 2019 ident: 2023072706474702600_bib5 article-title: Impaired control of multiple viral infections in a family with complete IRF9 deficiency publication-title: J. Allergy Clin. Immunol. doi: 10.1016/j.jaci.2019.02.019 – volume: 3 year: 2006 ident: 2023072706474702600_bib30 article-title: Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1 publication-title: PLoS Med. doi: 10.1371/journal.pmed.0030289 – volume: 50 start-page: 907 year: 2019 ident: 2023072706474702600_bib21 article-title: Shared and Distinct Functions of Type I and Type III Interferons publication-title: Immunity. doi: 10.1016/j.immuni.2019.03.025 – volume: 7 year: 2011 ident: 2023072706474702600_bib47 article-title: Identification and characterization of the host protein DNAJC14 as a broadly active flavivirus replication modulator publication-title: PLoS Pathog. doi: 10.1371/journal.ppat.1001255 – year: 2020 ident: 2023072706474702600_bib11 article-title: A novel case of homozygous IFNAR1 deficiency with haemophagocytic lymphohistiocytosis publication-title: Clin. Infect. Dis. doi: 10.1093/cid/ciaa1790 – volume: 5 year: 2020 ident: 2023072706474702600_bib34 article-title: Human inborn errors of immunity: An expanding universe publication-title: Sci. Immunol. doi: 10.1126/sciimmunol.abb1662 – volume: 9 start-page: 72 year: 2019 ident: 2023072706474702600_bib16 article-title: Anti-Cytokine Autoantibodies in Systemic Lupus Erythematosus publication-title: Cells. doi: 10.3390/cells9010072 – volume: 25 start-page: 2078 year: 2009 ident: 2023072706474702600_bib24 article-title: The Sequence Alignment/Map format and SAMtools publication-title: Bioinformatics. doi: 10.1093/bioinformatics/btp352 – volume: 30 start-page: 5038 year: 2012 ident: 2023072706474702600_bib10 article-title: Viscerotropic disease: case definition and guidelines for collection, analysis, and presentation of immunization safety data publication-title: Vaccine. doi: 10.1016/j.vaccine.2012.04.067 |
| SSID | ssj0014456 |
| Score | 2.666962 |
| Snippet | Yellow fever virus (YFV) live attenuated vaccine can, in rare cases, cause life-threatening disease, typically in patients with no previous history of severe... Yellow fever virus live attenuated vaccine can rarely cause life-threatening disease. Inherited IFNAR1 deficiency was previously reported in one patient. Here,... |
| SourceID | pubmedcentral proquest pubmed crossref |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
| SubjectTerms | Adolescent Adult Aged Antibodies, Neutralizing - immunology Autoantibodies - immunology Autoimmune Diseases - genetics Autoimmune Diseases - immunology Brief Definitive Report COVID-19 - genetics COVID-19 - immunology Female Genetic Diseases, Inborn - genetics Genetic Diseases, Inborn - immunology HEK293 Cells Human Disease Genetics Humans Immunodeficiency Innate Immunity and Inflammation Interferon-alpha - genetics Interferon-alpha - immunology Male Middle Aged Receptor, Interferon alpha-beta - deficiency Receptor, Interferon alpha-beta - immunology SARS-CoV-2 - genetics SARS-CoV-2 - immunology Vaccines, Attenuated - genetics Vaccines, Attenuated - immunology Yellow Fever Vaccine - adverse effects Yellow Fever Vaccine - genetics Yellow Fever Vaccine - immunology Yellow fever virus - genetics Yellow fever virus - immunology |
| Title | Auto-antibodies to type I IFNs can underlie adverse reactions to yellow fever live attenuated vaccine |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/33544838 https://www.proquest.com/docview/2487153487 https://pubmed.ncbi.nlm.nih.gov/PMC7871457 |
| Volume | 218 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9swFBZZB2MvY_dlNzTYnoI3R5Zvj6W0JIP1qYW8GV2pR2qPzFnZfsV-8s6RbcW5DLpBEMGSHOPz5eiTzo2Q99NpYvJMJUEkRRLwXJhAwioVCGO50TqCj_PyPU9ml_zzIl6MRr8HXkvrRn5Uvw7GlfyPVOEayBWjZP9Bsv6mcAG-g3yhBQlDeysZH6-bOoBXU8oanQEdj8Qj1flkfnaOWacrV-Z2BTwTjf3A9LBIShvK4Eb_RNPLzcQa6Jss0YkI021Wa4E89IdQ3ur-dQOqAYXdKg-wZ6UXQDxXes_9EP30y2Wp2-QGp0tjXQxi7cn9rLb2uqvdPIOVNJiZsgJ17Q-uT65k6WoRY6TRjRgeXLCp83eJh8oY9sHopNEuRZ3-5SFalLOhgmYbDd0fP-wp_jDjqPgNJhdgmKftQH7tnXXPeyM6O3zGC5hd9LPvkLssBTaG4eML7zQEu09XD9g_ehdKAbM_DX97m-Ts7Vx2HXAHjObiIXnQyZEet7h6REamekzufenE-ISYHXjRpqYILzqnCC8K8KI9vGgHL-rhhaNbeFEHL4rwoht40Q5eT8nl2enFySzoqnIEisdhE0yZUbDJVGkmU40ZNZlIZJRoTMWoM5tYmbKI2zAVWa6Z5szmQvJYpwzZaKKiZ-SoqivzgtAQOyxXwIk5Z0qITEWh4FZHTKpcyTGZ9K-xUF3KeqycsiwOiWxMPvjR39pULX8Z966XSAG6FA1kojL1-nsBvSkwAGjH5HkrIX-nKIo5z6JsTNIt2fkBmKd9u6cqr1y-dlgTpzxOX97y-V6R-5u_y2ty1KzW5g0w30a-dWD8A3b_s-w |
| linkProvider | Geneva Foundation for Medical Education and Research |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Auto-antibodies+to+type+I+IFNs+can+underlie+adverse+reactions+to+yellow+fever+live+attenuated+vaccine&rft.jtitle=The+Journal+of+experimental+medicine&rft.au=Bastard%2C+Paul&rft.au=Michailidis%2C+Eleftherios&rft.au=Hoffmann%2C+Hans-Heinrich&rft.au=Chbihi%2C+Marwa&rft.date=2021-04-05&rft.issn=0022-1007&rft.eissn=1540-9538&rft.volume=218&rft.issue=4&rft_id=info:doi/10.1084%2Fjem.20202486&rft.externalDBID=n%2Fa&rft.externalDocID=10_1084_jem_20202486 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-1007&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-1007&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-1007&client=summon |